{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear-cell+Kidney+Carcinoma&page=2", "query": { "condition": "Clear-cell Kidney Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear-cell+Kidney+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T14:56:49.875Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07578025", "title": "Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-11-28", "completion_date": "2028-06-24", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07578025" }, { "nct_id": "NCT06661720", "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma (RCC)", "Stage II Renal Pelvis Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Tivozanib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "MRI", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1040, "start_date": "2025-03-14", "completion_date": "2037-11", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 415, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 332 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06661720" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT00002611", "title": "Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "0 Years to 15 Years" }, "enrollment_count": 3031, "start_date": "1995-07", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 206, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002611" }, { "nct_id": "NCT04300140", "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Batiraxcept", "type": "DRUG" }, { "name": "Cabozantinib (Cabo)", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aravive, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-02-26", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 17, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 13 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300140" }, { "nct_id": "NCT00049296", "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-07", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049296" }, { "nct_id": "NCT03428217", "title": "CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2018-04-24", "completion_date": "2021-07-16", "has_results": true, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428217" }, { "nct_id": "NCT00589550", "title": "PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "PEG-interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER" ], "sponsor": "Thomas Olencki", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-02", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589550" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 581, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 377 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT00027820", "title": "Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Myelodysplastic Syndrome", "Childhood Renal Cell Carcinoma", "Chronic Myelomonocytic Leukemia", "Clear Cell Renal Cell Carcinoma", "de Novo Myelodysplastic Syndrome", "Metastatic Renal Cell Cancer", "Previously Treated Myelodysplastic Syndrome", "Progression of Multiple Myeloma or Plasma Cell Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Refractory Anemia", "Refractory Anemia With Ringed Sideroblasts", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Renal Medullary Carcinoma", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 106, "start_date": "2001-08", "completion_date": "2004-09-05", "has_results": false, "last_update_posted_date": "2019-12-20", "last_synced_at": "2026-07-23T14:56:49.875Z", "location_count": 8, "location_summary": "Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" }, { "city": "Garland", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027820" } ] }